Prime Medicine, Inc. Stock Analysis & AI Score
Prime Medicine, Inc. (PRME) has an ST Score of 32.5 (C-), driven by its Forecast (A) and held back by its Profitability (F). Analysts rate it Buy with a $7.50 price target (+144.3% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Prime Medicine, Inc. (PRME) has an ST Score of 32.5 (C-), driven by its Forecast (A) and held back by its Profitability (F). Analysts rate it Buy with a $7.50 price target (+144.3% upside).
- Strongest
- ForecastA
- Weakest
- ProfitabilityF
All factor grades
- ForecastA
- ValuationC
- MomentumC-
- GrowthC-
- Financial StrengthD
- ProfitabilityF
- Piotroski2/9
Contact
PRME stock: frequently asked questions
What is PRME's ST Score?
Prime Medicine, Inc. (PRME) has an ST Score of 32.5 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is PRME a buy, hold, or sell?
Analysts rate PRME a Buy, with a price target of $7.50 (+144.3% vs the current price). Our ST Score grades it C- (32.5/100). The ST Score is a data-driven signal, not a recommendation.
What are PRME's factor grades?
Valuation C, Profitability F, Financial Strength D, Momentum C-, Growth C-, Forecast A.
What is PRME's valuation grade?
Prime Medicine, Inc. (PRME) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is PRME's growth grade?
Prime Medicine, Inc. (PRME) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is PRME's profitability grade?
Prime Medicine, Inc. (PRME) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is PRME's financial strength grade?
Prime Medicine, Inc. (PRME) earns a financial strength grade of D, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for PRME?
The average analyst price target for Prime Medicine, Inc. (PRME) is $7.50 from 10 analysts, which is +144.3% versus the recent price of $3.07.
What is PRME's Piotroski score?
Prime Medicine, Inc. (PRME) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.